

Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation

Martin Bommer, Stephanie von Harsdorf, Hartmut Döhner, Donald Bunjes,* and Mark Ringhoffer**

Department of Internal Medicine III, University Hospital of Ulm, Germany


Citation: Bommer M, von Harsdorf S, Döhner H, Bunjes D, and Ringhoffer M. Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation. *Haematologica* 2010;95(11):1969-1972.
doi:10.3324/haematol.2010.025999

Online Supplementary TableS1. Patients' characteristics.

Patients with AML transplanted (N. of patients)	250	
LP performed	204	82%
median time between index LP and HSCT (days)	16	
Age, median	48	
Cytogenetics available	178	87%
Poor risk*	34	19%
Intermediate risk*	123	69%
Favorable risk*	21	12%
Remission status at transplantation		
CR1	95	47%
>CR1, PR	56	27%
RD	53	26%
Donor		
MR		
D	88	43%
MU		
D	111	54%
Haploidentical donor	5	2%
Conditioning regimen		
Standard intensity	120	59%
Reduced intensity (RIC)	84	41%
CNS disease at any time	31	15%
Age, median	43	
Cytogenetics available	29	
Poor risk*	3	10%
Intermediate risk*	22	76%
Favorable risk*	4	14%
Remission status at transplantation		
CR1	7	23%
>CR1, PR	9	29%
RD	15	48%
Donor		
MRD	11	35%
MUD	18	58%
Haploidentical donor	2	6%
Conditioning regimen		
Standard intensity (incidence of CNS disease)	18	15%
Reduced intensity (incidence of CNS disease)	13	16%
CNS disease diagnosed before HSCT	26	13%
CNS disease successfully treated before HSCT	9	
Intrathecal methotrexate (average cumulative dose)	5	(65mg)
Intrathecal ARA-C (average cumulative dose)	7	(188mg)
Intrathecal liposomal ARA-C (average cumulative dose)	0	
CNS radiotherapy (dose)	1	(14 Gy)
HD-ARA-C	9	
CNS disease active at index LP	17	8%
Age, median	49	
known from previous treatment courses	9	

to be continued in the next page

newly diagnosed at time-point of HSCT	8	
Patients with refractory leukemia	10	
Patients with poor risk karyotype	2	
CNS targeted treatment pre-HSCT	17	
Intrathecal methotrexate (average cumulative dose)	14	(46,3 mg)
Intrathecal ARA-C (average cumulative dose)	9	(156mg)
Intrathecal liposomal ARA-C (average cumulative dose)	5	(120 mg)
CNS radiotherapy (average dose)	3	(25,2 Gy)
CNS targeted treatment after HSCT	10	
Intrathecal methotrexate (average cumulative dose)	5	(31,2mg)
Intrathecal ARA-C (average cumulative dose)	2	(60mg)
Intrathecal liposomal ARA-C (average cumulative dose)	4	(150mg)
CNS radiotherapy (average dose)	2	(21.6 Gy)
CNS disease after HSCT	8	4%
Median time from HSCT to diagnosis of CNS relapse (days)	203	
CNS disease relapse after HSCT	3	
Pt. recieved post-HSCT maintainance therapy	2	
CNS disease newly diagnosed after HSCT	5	
Free of CNS disease at any time	173	85%
Age, median	48	
Cytogenetics available	149	
Poor risk*	31	18%
Intermediate risk*	101	58%
Favorable risk*	17	10%
Remission status at transplantation		
CR1	88	51%
>CR1, PR	47	27%
RD	38	22%
Donor		
MRD	77	45%
MUD	93	54%
Haploidentical donor	3	2%
Conditioning regimen		
Standard intensity	102	59%
Reduced intensity (RIC)	70	40%
Previous exposure to CNS active therapy before LP	143	83%
	HD-ARA-C	142
	HD-ARA-C/TBI	1
*Favorable risk: t(15;17)(q22;q21); t(8;21)(q22;q22); inv(16)(p13q22)/t(16;16)(p13;q22). Intermediate risk: neither favorable nor poor risk aberration, normal karyotype. Poor risk: abn(3q) [excluding t(3;5)(q21~25;q31~35)],; inv(3)(q21q26)/t(3;3)(q21;q26), add(5q), del(5q), -5, -7, add(7q)/del(7q), t(6;11)(q27;q23), t(10;11)(p11~13;q23), t(11q23) [excluding t(9;11)(p21~22;q23) & t(11;19)(q23;p13)], t(9;22)(q34;q11), -17/abn(17p), Complex (≥4 unrelated abnormalities)		
Abbreviations: LP lumbar puncture, HSCT hematopoietic stem cell transplantation, CNS central nervous system, HD-ARA-C high-dose cytarabine, i.th. Intrathecal therapy, RT radiotherapy, MUD = matched unrelated donor, MRD = matched related donor, CR1=first complete remission, PR=partial remission, RD=refractory disease,		



Online Supplementary Figure S1. Flow chart of patients included in the analysis.